Targeting the cancer glycocalyx to improve immune response
Targeting the cancer glycocalyx
This study is looking at how cancer cells change their surface sugars to hide from the immune system, and it's for people with cancer who want better treatment options; the goal is to create new therapies that help the immune system recognize and fight the cancer more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11065524 on NIH RePORTER |
What this research studies
This research investigates how cancer cells alter their surface sugars, which helps them evade the immune system. By understanding these changes, the study aims to develop new therapies that can break this immune suppression. The approach includes creating specialized antibodies that can degrade the sugars on cancer cells, making them more visible to the immune system. This could enhance the effectiveness of existing cancer treatments and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients whose tumors exhibit altered glycosylation patterns, particularly those with aggressive disease.
Not a fit: Patients with non-cancerous conditions or those whose tumors do not show the specific glycosylation changes targeted by this research may not benefit.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer therapies that improve immune responses and patient survival rates.
How similar studies have performed: Previous research has shown promise in targeting glycosylation patterns in cancer, indicating that this approach could be a significant advancement in cancer treatment.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Bertozzi, Carolyn — Stanford University
- Study coordinator: Bertozzi, Carolyn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.